Ladenburg Thalmann Financial Services assumed coverage on shares of Avinger (NASDAQ:AVGR) in a research report report published on Friday, Marketbeat.com reports. The brokerage issued a buy rating on the medical device company’s stock.
Separately, Zacks Investment Research raised Avinger from a hold rating to a buy rating and set a $10.00 target price for the company in a research report on Wednesday, January 3rd. Four equities research analysts have rated the stock with a hold rating and two have given a buy rating to the company. The company has a consensus rating of Hold and an average price target of $10.00.
Avinger (NASDAQ AVGR) opened at $1.29 on Friday. The firm has a market capitalization of $1.06, a PE ratio of -0.01 and a beta of 0.88. Avinger has a 52-week low of $0.95 and a 52-week high of $86.00.
TRADEMARK VIOLATION WARNING: This report was originally published by Markets Daily and is owned by of Markets Daily. If you are viewing this report on another website, it was illegally stolen and republished in violation of US and international trademark & copyright laws. The original version of this report can be accessed at https://www.themarketsdaily.com/2018/03/13/avinger-avgr-coverage-initiated-by-analysts-at-ladenburg-thalmann-financial-services.html.
Avinger Company Profile
Avinger, Inc is a commercial-stage medical device company. The Company designs, manufactures and sells image-guided, catheter-based systems that are used by physicians to treat patients with peripheral arterial disease (PAD). The Company focuses on introducing products based on its lumivascular platform, which is an intravascular image-guided system.
Receive News & Ratings for Avinger Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Avinger and related companies with MarketBeat.com's FREE daily email newsletter.